Cargando…

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

AIMS: There is no cure for pulmonary arterial hypertension, but current approved treatment options include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors. The effect on survival of these compounds has not been appropriately assessed in individual trials because...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galiè, Nazzareno, Manes, Alessandra, Negro, Luca, Palazzini, Massimiliano, Bacchi-Reggiani, Maria Letizia, Branzi, Angelo
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2009
Materias:	FASTTrack
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2642921/ https://www.ncbi.nlm.nih.gov/pubmed/19155250 http://dx.doi.org/10.1093/eurheartj/ehp022

Ejemplares similares

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
por: Galiè, Nazzareno, et al.
Publicado: (2010)

GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
por: Palazzini, Massimiliano, et al.
Publicado: (2023)

A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension
por: Barozzi, Chiara, et al.
Publicado: (2019)

Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors
por: Dardi, Fabio, et al.
Publicado: (2023)

Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial
por: Worthley, Stephen G., et al.
Publicado: (2013)

Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation
por: Hjortnaes, Jesper, et al.
Publicado: (2010)

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
por: Steg, Ph. Gabriel, et al.
Publicado: (2011)

The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy
por: Gold, Michael R., et al.
Publicado: (2011)

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy
por: Tardif, Jean-Claude, et al.
Publicado: (2011)

One year follow-up of the multi-centre European PARTNER transcatheter heart valve study
por: Lefèvre, Thierry, et al.
Publicado: (2011)

Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation
por: Matsa, Elena, et al.
Publicado: (2011)

Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study
por: Tanaka, Hidekazu, et al.
Publicado: (2010)

Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter
por: Templin, Christian, et al.
Publicado: (2013)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
por: Steg, Ph Gabriel, et al.
Publicado: (2012)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

Beyond the World Symposium on Pulmonary Hypertension: practical management of pulmonary arterial hypertension and evolving concepts
por: Vachiéry, Jean-Luc, et al.
Publicado: (2019)

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
por: Goto, Shinya, et al.
Publicado: (2010)

Pulmonary Arterial Hypertension: Combination Therapy in Practice
por: Burks, Marsha, et al.
Publicado: (2018)

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve
por: Bairey Merz, C. Noel, et al.
Publicado: (2016)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
por: Haynes, Richard, et al.
Publicado: (2013)

Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study(†)
por: Budera, Petr, et al.
Publicado: (2012)

The burden of comorbidities in pulmonary arterial hypertension
por: Lang, Irene M, et al.
Publicado: (2019)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction—a hospital registry-primary care linked cohort (MINAP–GPRD)
por: Boggon, Rachael, et al.
Publicado: (2011)

Variants in the 3′ untranslated region of the KCNQ1-encoded K(v)7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner
por: Amin, Ahmad S., et al.
Publicado: (2012)

A novel clinical method for quantification of regional left ventricular pressure–strain loop area: a non-invasive index of myocardial work
por: Russell, Kristoffer, et al.
Publicado: (2012)

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation
por: Lauten, Alexander, et al.
Publicado: (2011)

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
por: Pitt, Bertram, et al.
Publicado: (2011)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

The German Aortic Valve Registry (GARY): in-hospital outcome
por: Hamm, Christian W., et al.
Publicado: (2014)

Impact of cardiac magnetic resonance imaging on human lymphocyte DNA integrity
por: Fiechter, Michael, et al.
Publicado: (2013)

Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
por: Metra, Marco, et al.
Publicado: (2013)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium(†)
por: Riegger, Julia, et al.
Publicado: (2016)

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2016)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial
por: Haude, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7difhquoun5g4kirutn97kag5i